Vial switch improves life-saving antiviral drug22 Apr 2019
Legacy Pharmaceuticals uses SCHOTT Type I Plus vials to overcome a leaching issue.
Legacy Pharmaceuticals, a Swiss-based global contract manufacturer of sterile/aseptic pharmaceutical products in ampoules and vials, is collaborating with SCHOTT, a leading company in innovative glass production and technology, to solve a technical challenge. Legacy turned to SCHOTT Type I Plus vials to overcome a leaching issue for a life-saving antiviral drug product. This was successful, and Legacy and SCHOTT are now offering this solution to future customers with a need to provide better stability, particularly for highly sensitive formulations.
Protein adsorption and leaching from primary packaging are known to be root causes of reduced shelf life in many formulations. Ion leaching, especially for sodium, aluminium and other metal ions, forms uncoated type I glass and leads to pH shift and decreased stability or activity of biopharmaceuticals. The SCHOTT Type I Plus vials have an inside SiO2 coating with outstanding barrier properties.
“The barrier layer in the vials comes with multiple benefits: it prevents depletion of the glass container by the drug formulation and also acts as a diffusion barrier for all leachables of the glass matrix, supressing them to a level below their respective detection limit. The diffusion barrier is certified by a release test with a limit for sodium leaching (0.17 mg/l) less then 1/10 of the required sodium level for Type 1 containers (2.4 mg/l),” says Dr Bernhard Hladik, Senior Business Development Manager at SCHOTT.
This reduces the interaction between drug product and container surface, thereby providing a superior packaging solution for sensitive drug products.
“The number of injectable drugs coming to market continues to grow. However, many of the new formulations are highly sensitive. This imposes increasing demands on primary packaging - both vials and stoppers. Drawing on our longstanding expertise and knowledge of APIs and buffer systems, we proactively looked for new solutions to meet our customer’s demands. We have now identified, and validated the SCHOTT Type I Plus vials as a reliable option for our customers,“ commented Mike Danzi, CEO of Legacy Pharmaceuticals.
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.Read more
Onyx Scientific makes strategic investment in commercial API licence
10 Jul 2019
Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.Read more
I Holland to share the science behind tool maintenance
9 Jul 2019
Proper maintenance - rather than replacement - of compression tooling will improve profitability.Read more
Catalent extends global commercial spray drying capabilities in Europe
9 Jul 2019
Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.Read more
Operations commence at Wasdell Group’s EU headquarters
8 Jul 2019
The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.Read more
Porvair Sciences launches first Drosophila ChIP kits
4 Jul 2019
Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.Read more
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound
3 Jul 2019
Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe
2 Jul 2019
The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.Read more
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra
1 Jul 2019
Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation